120 results
Page 2 of 6
8-K
EX-99.1
gpf152d
12 Feb 24
Results of Operations and Financial Condition
7:03am
8-K
EX-99.3
3owz83ult
12 Feb 24
Results of Operations and Financial Condition
7:03am
8-K
EX-99.2
plvb ce0yr2z
14 Nov 23
Larimar Therapeutics Reports Third Quarter 2023 Operating and Financial Results
12:00am
8-K
EX-99.1
xt88rcedaae
14 Nov 23
Larimar Therapeutics Reports Third Quarter 2023 Operating and Financial Results
12:00am
8-K
EX-99.1
12y 97vajeqqiq9
14 Aug 23
Other Events
8:00am
8-K
EX-99.1
n1pvlj6krtim 2qxba
10 Aug 23
Larimar Therapeutics Reports Second Quarter 2023 Operating and Financial Results
7:03am
8-K
EX-99.2
mfm8ytb pv73x3njtg99
25 Jul 23
Top-line safety, pharmacokinetic, and pharmacodynamic (frataxin level) data from Phase 2 trial’s 50 mg cohort expected in 1H 2024
7:02am
8-K
EX-99.1
s4wpk0 tjirr0mk
25 Jul 23
Top-line safety, pharmacokinetic, and pharmacodynamic (frataxin level) data from Phase 2 trial’s 50 mg cohort expected in 1H 2024
7:02am
8-K
EX-99.1
er0pb2iyu2515k2
1 Jun 23
June 2023 Larimar Therapeutics Corporate Presentation
4:06pm
8-K
EX-99.2
k1xgjqig ainq1c
15 May 23
Results of Operations and Financial Condition
7:05am
8-K
EX-99.2
mlierlej9
10 Nov 22
Larimar Therapeutics Reports Third Quarter 2022 Operating and Financial Results
7:01am
8-K
EX-99.1
pf2 h8s2g0azr
10 Nov 22
Larimar Therapeutics Reports Third Quarter 2022 Operating and Financial Results
7:01am
8-K
EX-99.1
pcgtzofa1xb9q9mle6
20 Oct 22
October 2022 Larimar Therapeutics Corporate Presentation
8:11am
8-K
EX-1.1
xer653gw0
14 Sep 22
Entry into a Material Definitive Agreement
9:01am
424B5
qy5g 58rau
14 Sep 22
Prospectus supplement for primary offering
7:28am